[Remnant gastric cancer in which prolonged no change status was maintained with low-dose TS-1--a case report]

Gan To Kagaku Ryoho. 2003 May;30(5):695-8.
[Article in Japanese]

Abstract

A no change (NC) status could be maintained in a patient with remnant gastric cancer for more than 500 days with low-dose TS-1. The patient was a 68-year-old woman who was found to have remnant gastric cancer during an endoscopic examination in follow-up on an outpatient basis after surgery for hepatocellular carcinoma in our department. Surgery was rejected as a treatment option because of severe liver dysfunction, and the patient was started on oral TS-1 80 mg/day. Both AST and ALT levels increased immediately after the start of TS-1, and TS-1 was discontinued until these levels improved. It was resumed at 50 mg/day, and there were no subsequent adverse reactions. Endoscopic examination on day 69 after the start of TS-1 showed that a partial response (PR) had not been achieved, but the lesion had shrunk. Endoscopy on day 454 after the start of TS-1 showed it had been possible to maintain a similar state. This was a rare case in which it was possible to achieve prolonged same status with low-dose TS-1.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / pathology
  • Administration, Oral
  • Aged
  • Antimetabolites, Antineoplastic / administration & dosage*
  • Carcinoma, Hepatocellular / surgery
  • Drug Administration Schedule
  • Drug Combinations
  • Female
  • Humans
  • Liver Neoplasms / surgery
  • Neoplasm, Residual
  • Neoplasms, Multiple Primary
  • Oxonic Acid / administration & dosage*
  • Pyridines / administration & dosage*
  • Stomach Neoplasms / drug therapy*
  • Stomach Neoplasms / pathology
  • Tegafur / administration & dosage*

Substances

  • Antimetabolites, Antineoplastic
  • Drug Combinations
  • Pyridines
  • S 1 (combination)
  • Tegafur
  • Oxonic Acid